As full-service provider, we support biopharmaceutical companies with orphan portfolios with all services starting from Named Patient Program till the commercialization of orphan drugs in 8 countries.
Develop Sanofi Genzyme business in Central Asia and Caucasus countries with launching new rare portfolio products in lysosomal disorders diseases
Set up diagnostic and patient support programs for Duchenne patients in Uzbekistan and Azerbaijan countries
Provide expanded access and treatment for new exon-skipping therapies for all eligible Duchenne Muscular diseases patients in Central Asia and Caucasus countries
Pharm&Access is operating and shaping market and environment in 8 countries through their partners to make innovative and orphan products/therapies available for rare disease patients as quickly as possible